DMK Pharmaceuticals Corporation Common Stock
DMK was delisted on the 6th of February, 2024.
58 hedge funds and large institutions have $18.7M invested in DMK Pharmaceuticals Corporation Common Stock in 2018 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 8 increasing their positions, 17 reducing their positions, and 9 closing their positions.
11% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 9
2% more funds holding
Funds holding: 57 → 58 (+1)
48% less capital invested
Capital invested by funds: $36.2M → $18.7M (-$17.5M)
53% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 17
77% less call options, than puts
Call options by funds: $229K | Put options by funds: $975K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$309K |
| 2 |
BlackRock
New York
|
+$204K |
| 3 |
Barclays
London,
United Kingdom
|
+$133K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$132K |
| 5 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$91.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DekaBank Deutsche Girozentrale
Frankfurt,
Germany
|
-$3.36M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$1.57M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.44M |
| 4 |
PA
Perceptive Advisors
New York
|
-$481K |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$346K |
DMK Hedge Fund Activity: Q4 2018 in Review
58 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in DMK Pharmaceuticals Corporation Common Stock (DMK) for Q4 2018, worth a combined $18.7M — down 48% from $36.2M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new DMK positions and 9 closed out — a net gain of 1 holder — while 8 added to existing stakes and 17 trimmed.
The largest buyer was Oxford Asset Management, opening a new position worth an estimated $309K. The largest seller was DekaBank Deutsche Girozentrale, exiting entirely with an estimated $3.36M sold.
- 58 institutional investors held DMK Pharmaceuticals Corporation Common Stock (DMK) as of Q4 2018, up from 57 in Q3 2018.
- Funds reported $18.7M of DMK Pharmaceuticals Corporation Common Stock stock for Q4 2018, down 48% quarter-over-quarter.
- 10 funds opened new DMK Pharmaceuticals Corporation Common Stock positions in Q4 2018 and 9 closed out, a net change of +1 holder.
- The largest DMK Pharmaceuticals Corporation Common Stock buyer in Q4 2018 was Oxford Asset Management, an estimated $309K added.
- The largest DMK Pharmaceuticals Corporation Common Stock seller in Q4 2018 was DekaBank Deutsche Girozentrale, an estimated $3.36M sold.
Based on aggregated 13F filings for Q4 2018.